BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int J Mol Sci 2020;21:E4002. [PMID: 32503307 DOI: 10.3390/ijms21114002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Y, Liu Z, Yang X, Liu L, Ahn KS. An updated review on the potential antineoplastic actions of oleuropein. Phytother Res 2021. [PMID: 34808696 DOI: 10.1002/ptr.7325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhu S, Yang N, Niu C, Wang W, Wang X, Bai J, Qiao Y, Deng S, Guan Y, Chen J. The miR-145–MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106196] [Reference Citation Analysis]
3 Martínez-rodríguez OP, González-torres A, Álvarez-salas LM, Hernández-sánchez H, García-pérez BE, Thompson-bonilla MDR, Jaramillo-flores ME. Effect of naringenin and its combination with cisplatin in cell death, proliferation and invasion of cervical cancer spheroids. RSC Adv 2021;11:129-41. [DOI: 10.1039/d0ra07309a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choi HS, Kim YK, Yun PY. Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis. Int J Mol Sci 2021;22:8167. [PMID: 34360933 DOI: 10.3390/ijms22158167] [Reference Citation Analysis]
5 Zuchegna C, Di Zazzo E, Moncharmont B, Messina S. Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement. BMC Res Notes 2020;13:374. [PMID: 32771050 DOI: 10.1186/s13104-020-05214-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jones C, Dziadowicz S, Suite S, Eby A, Chen W, Hu G, Hazlehurst LA. Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines. Cancers 2022;14:3062. [DOI: 10.3390/cancers14133062] [Reference Citation Analysis]
7 Zhai Y, Shan C, Zhang H, Kong P, Zhang L, Wang Y, Hu X, Cheng X. FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma. Mol Cell Biochem 2022. [PMID: 35606602 DOI: 10.1007/s11010-022-04475-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Liu T, Zhang Z, Wang C, Huang H, Li Y. BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance. Biochem Cell Biol 2022;:1-9. [PMID: 35167374 DOI: 10.1139/bcb-2021-0552] [Reference Citation Analysis]
9 Girisa S, Saikia Q, Bordoloi D, Banik K, Monisha J, Daimary UD, Verma E, Ahn KS, Kunnumakkara AB. Xanthohumol from Hop: Hope for cancer prevention and treatment. IUBMB Life 2021;73:1016-44. [PMID: 34170599 DOI: 10.1002/iub.2522] [Reference Citation Analysis]
10 Ashrafizadeh M, Rabiee N, Prem Kumar A, Sethi G, Zarrabi A, Wang Y. Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discov Today 2022:S1359-6446(22)00202-1. [PMID: 35589014 DOI: 10.1016/j.drudis.2022.05.012] [Reference Citation Analysis]
11 Kozak J, Forma A, Czeczelewski M, Kozyra P, Sitarz E, Radzikowska-Büchner E, Sitarz M, Baj J. Inhibition or Reversal of the Epithelial-Mesenchymal Transition in Gastric Cancer: Pharmacological Approaches. Int J Mol Sci 2020;22:E277. [PMID: 33383973 DOI: 10.3390/ijms22010277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Mirzaei S, Gholami MH, Zabolian A, Saleki H, Farahani MV, Hamzehlou S, Far FB, Sharifzadeh SO, Samarghandian S, Khan H, Aref AR, Ashrafizadeh M, Zarrabi A, Sethi G. Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. Pharmacol Res 2021;171:105759. [PMID: 34245864 DOI: 10.1016/j.phrs.2021.105759] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Wang Y, Zhang J, Zhong LY, Huang SJ, Yu NN, Ouyang L, Niu YL, Chen JX, Lu CH, He QY. Hsa-miR-335 enhances cell migration and invasion in lung adenocarcinoma through targeting Copine-1. MedComm (2020) 2021;2:810-20. [PMID: 34977878 DOI: 10.1002/mco2.93] [Reference Citation Analysis]
14 Han W, Yu F, Guan W. Oncogenic roles of lncRNA BLACAT1 and its related mechanisms in human cancers. Biomed Pharmacother 2020;130:110632. [PMID: 34321169 DOI: 10.1016/j.biopha.2020.110632] [Reference Citation Analysis]
15 Kielbik M, Szulc-Kielbik I, Klink M. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level. Int J Mol Sci 2021;22:980. [PMID: 33478150 DOI: 10.3390/ijms22020980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang N, Xu Y, Guo Q, Zhu C, Zhao W, Qian W, Zheng M. Effects of miR-132-3p on progress and epithelial mesenchymal transition of non-small cell lung cancer via regulating KLF7. J Thorac Dis 2021;13:2426-36. [PMID: 34012590 DOI: 10.21037/jtd-21-353] [Reference Citation Analysis]
17 Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene 2021;40:6395-405. [PMID: 34645978 DOI: 10.1038/s41388-021-02055-2] [Reference Citation Analysis]
18 Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. Pharmacol Res 2022;:106311. [PMID: 35716914 DOI: 10.1016/j.phrs.2022.106311] [Reference Citation Analysis]
19 Zou Y, Li JJ, Xue W, Kong X, Duan H, Li Y, Wei L. Epigenetic Modifications and Therapy in Uveitis. Front Cell Dev Biol 2021;9:758240. [PMID: 34869347 DOI: 10.3389/fcell.2021.758240] [Reference Citation Analysis]
20 Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel) 2021;10:349. [PMID: 33652780 DOI: 10.3390/antiox10030349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
21 Cheng Y, Li S, Gao L, Zhi K, Ren W. The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:761379. [PMID: 34746001 DOI: 10.3389/fonc.2021.761379] [Reference Citation Analysis]
22 Tsuji T, Hosoda A, Toriyama Y, Yoshida Y, Kohno T. Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice. Transl Oncol 2022;18:101369. [PMID: 35182957 DOI: 10.1016/j.tranon.2022.101369] [Reference Citation Analysis]
23 Jung YY, Baek SH, Narula AS, Namjoshi OA, Blough BE, Ahn KS. Potential function of oxymatrine as a novel suppressor of epithelial-to-mesenchymal transition in lung tumor cells. Life Sci 2021;284:119893. [PMID: 34454947 DOI: 10.1016/j.lfs.2021.119893] [Reference Citation Analysis]
24 Choi HS, Kim Y, Yun P. Assessing Gene Expression Related to Cisplatin Resistance in Human Oral Squamous Cell Carcinoma Cell Lines. Pharmaceuticals 2022;15:704. [DOI: 10.3390/ph15060704] [Reference Citation Analysis]
25 Shi Q, Chen Q, Zhou Z, Zheng X, Huang X, Fang M, Hu Y, Song L, Yang H, Chen Q. Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer. Pulm Pharmacol Ther 2021;69:102048. [PMID: 34082109 DOI: 10.1016/j.pupt.2021.102048] [Reference Citation Analysis]
26 Mirzaei S, Abadi AJ, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Zarrabi A, Entezari M, Aref AR, Khan H, Ashrafizadeh M, Samarghandian S. The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets. Eur J Pharmacol 2021;908:174344. [PMID: 34270987 DOI: 10.1016/j.ejphar.2021.174344] [Reference Citation Analysis]
27 Lee J, You JH, Kim MS, Roh JL. Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer. Redox Biol 2020;37:101697. [PMID: 32896720 DOI: 10.1016/j.redox.2020.101697] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
28 Ray A, Kunhiraman H, Perera RJ. The Paradoxical Behavior of microRNA-211 in Melanomas and Other Human Cancers. Front Oncol 2020;10:628367. [PMID: 33628737 DOI: 10.3389/fonc.2020.628367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Jung YY, Chinnathambi A, Alahmadi TA, Alharbi SA, Kumar AP, Sethi G, Ahn KS. Fangchinoline targets epithelial-mesenchymal transition process by modulating activation of multiple cell-signaling pathways. J Cell Biochem 2022. [PMID: 35621239 DOI: 10.1002/jcb.30279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Sharma V, Letson J, Furuta S. Fibrous stroma: Driver and passenger in cancer development. Sci Signal 2022;15:eabg3449. [PMID: 35258999 DOI: 10.1126/scisignal.abg3449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G, Tergaonkar V. NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol 2022. [PMID: 35561232 DOI: 10.1002/jcp.30759] [Reference Citation Analysis]
33 Liu Y, Lai S, He J, Wan J, Fu F, Jinlong Y. Targeting RPL23 restores chemosensitivity of cisplatin-resistant ovarian carcinoma by inhibiting EMT. Cytotechnology. [DOI: 10.1007/s10616-022-00535-1] [Reference Citation Analysis]
34 Koguchi D, Matsumoto K, Shimizu Y, Kobayashi M, Hirano S, Ikeda M, Sato Y, Iwamura M. Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy. Cancers (Basel) 2021;13:1748. [PMID: 33918555 DOI: 10.3390/cancers13081748] [Reference Citation Analysis]
35 Alghamian Y, Soukkarieh C, Abbady AQ, Murad H. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line. Sci Rep 2022;12:7494. [PMID: 35523936 DOI: 10.1038/s41598-022-11634-6] [Reference Citation Analysis]
36 Napoletano C, Steentoff C, Battisti F, Ye Z, Rahimi H, Zizzari IG, Dionisi M, Cerbelli B, Tomao F, French D, d'Amati G, Panici PB, Vakhrushev S, Clausen H, Nuti M, Rughetti A. Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). Cancers (Basel) 2020;12:E2841. [PMID: 33019700 DOI: 10.3390/cancers12102841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Rahmanian V, Entezari M, Girish YR, Sharath Kumar KS, Aref AR, Makvandi P, Ashrafizadeh M, Zarrabi A, Khan H. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy. Life Sci 2021;277:119430. [PMID: 33789144 DOI: 10.1016/j.lfs.2021.119430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
38 You JH, Lee J, Roh JL. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition. Cancer Lett 2021;507:40-54. [PMID: 33741422 DOI: 10.1016/j.canlet.2021.03.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
39 Donix L, Erb HHH, Peitzsch C, Dubrovska A, Pfeifer M, Thomas C, Fuessel S, Erdmann K. Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines. J Cancer Res Clin Oncol 2022. [PMID: 35020044 DOI: 10.1007/s00432-022-03914-5] [Reference Citation Analysis]
40 Posch F, Prinz F, Balihodzic A, Mayr C, Kiesslich T, Klec C, Jonas K, Barth DA, Riedl JM, Gerger A, Pichler M. MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms. Cancers (Basel) 2021;13:3996. [PMID: 34439151 DOI: 10.3390/cancers13163996] [Reference Citation Analysis]
41 Rishabh K, Khadilkar S, Kumar A, Kalra I, Kumar AP, Kunnumakkara AB. MicroRNAs as Modulators of Oral Tumorigenesis-A Focused Review. Int J Mol Sci 2021;22:2561. [PMID: 33806361 DOI: 10.3390/ijms22052561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Moschetta-Pinheiro MG, Colombo J, Godoy BLV, Balan JF, Nascimento BC, Zuccari DAPC. Modulation of Epithelial Mesenchymal Transition after AGTR-1 Gene Edition by Crispr/Cas9 and Losartan Treatment in Mammary Tumor Cell Line: A Comparative Study between Human and Canine Species. Life (Basel) 2021;11:1427. [PMID: 34947958 DOI: 10.3390/life11121427] [Reference Citation Analysis]
43 Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol 2021;13:303-28. [PMID: 33776489 DOI: 10.2147/JEP.S267383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
44 Su KM, Gao HW, Chang CM, Lu KH, Yu MH, Lin YH, Liu LC, Chang CC, Li YF, Chang CC. Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis. Biomedicines 2021;9:866. [PMID: 34440070 DOI: 10.3390/biomedicines9080866] [Reference Citation Analysis]
45 Mirzaei S, Hushmandi K, Zabolian A, Saleki H, Torabi SMR, Ranjbar A, SeyedSaleh S, Sharifzadeh SO, Khan H, Ashrafizadeh M, Zarrabi A, Ahn KS. Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies. Molecules 2021;26:2382. [PMID: 33921908 DOI: 10.3390/molecules26082382] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
46 Datta A, Deng S, Gopal V, Yap KC, Halim CE, Lye ML, Ong MS, Tan TZ, Sethi G, Hooi SC, Kumar AP, Yap CT. Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis. Cancers (Basel) 2021;13:1882. [PMID: 33919917 DOI: 10.3390/cancers13081882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
47 Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Reference Citation Analysis]
48 Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzeziańska-Lasota E. Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy. Int J Mol Sci 2021;22:8885. [PMID: 34445588 DOI: 10.3390/ijms22168885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Mirzaei S, Paskeh MDA, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, Hashemi M, Aref AR, Hushmandi K, Kumar AP, Rabiee N, Ashrafizadeh M, Samarghandian S. Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator? Int J Biol Macromol 2022:S0141-8130(22)00340-3. [PMID: 35202639 DOI: 10.1016/j.ijbiomac.2022.02.094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ashrafizadeh M, Hushmandi K, Hashemi M, Akbari ME, Kubatka P, Raei M, Koklesova L, Shahinozzaman M, Mohammadinejad R, Najafi M, Sethi G, Kumar AP, Zarrabi A. Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder Cancer. Biomolecules 2020;10:E1159. [PMID: 32784711 DOI: 10.3390/biom10081159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
51 Fichtner A, Bohnenberger H, Elakad O, Richter A, Lenz C, Oing C, Ströbel P, Kueffer S, Nettersheim D, Bremmer F. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry. World J Urol 2022. [PMID: 35084545 DOI: 10.1007/s00345-022-03936-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Rana V, Parama D, Khatoon E, Girisa S, Sethi G, Kunnumakkara AB. Reiterating the Emergence of Noncoding RNAs as Regulators of the Critical Hallmarks of Gall Bladder Cancer. Biomolecules 2021;11:1847. [PMID: 34944491 DOI: 10.3390/biom11121847] [Reference Citation Analysis]
53 Morelli AP, Tortelli TC Jr, Mancini MCS, Pavan ICB, Silva LGS, Severino MB, Granato DC, Pestana NF, Ponte LGS, Peruca GF, Pauletti BA, Dos Santos DFG Jr, de Moura LP, Bezerra RMN, Leme AFP, Chammas R, Simabuco FM. STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma. Neoplasia 2021;23:1048-58. [PMID: 34543857 DOI: 10.1016/j.neo.2021.08.003] [Reference Citation Analysis]
54 Rahman MA, Ahmed KR, Rahman MH, Park MN, Kim B. Potential Therapeutic Action of Autophagy in Gastric Cancer Managements: Novel Treatment Strategies and Pharmacological Interventions. Front Pharmacol 2022;12:813703. [DOI: 10.3389/fphar.2021.813703] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hu P, So K, Chen H, Lin Q, Xu M, Lin Y. A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition. Int J Immunopathol Pharmacol 2022;36:3946320221105134. [PMID: 35649742 DOI: 10.1177/03946320221105134] [Reference Citation Analysis]
56 Hires M, Jane E, Kalavska K, Chovanec M, Mego M, Kasak P, Bertok T, Tkac J. Glycan signatures for the identification of cisplatin‐resistant testicular cancer cell lines: Specific glycoprofiling of human chorionic gonadotropin (hCG). Cancer Medicine. [DOI: 10.1002/cam4.4515] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Biagioni A, Tavakol S, Ahmadirad N, Zahmatkeshan M, Magnelli L, Mandegary A, Samareh Fekri H, Asadi MH, Mohammadinejad R, Ahn KS. Small nucleolar RNA host genes promoting epithelial-mesenchymal transition lead cancer progression and metastasis. IUBMB Life 2021;73:825-42. [PMID: 33938625 DOI: 10.1002/iub.2501] [Reference Citation Analysis]
58 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Ashrafizadeh M, Mirzaei S, Hushmandi K, Rahmanian V, Zabolian A, Raei M, Farahani MV, Goharrizi MASB, Khan H, Zarrabi A, Samarghandian S. Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects. Life Sci 2021;278:119649. [PMID: 34043989 DOI: 10.1016/j.lfs.2021.119649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wu JY, Weng YS, Chiou YC, Hsu FT, Chiang IT. Induction of Apoptosis and Inhibition of EGFR/NF-κB Signaling Are Associated With Regorafenib-sensitized Non-small Cell Lung Cancer to Cisplatin. In Vivo 2021;35:2569-76. [PMID: 34410944 DOI: 10.21873/invivo.12539] [Reference Citation Analysis]
61 Mahabady MK, Mirzaei S, Saebfar H, Gholami MH, Zabolian A, Hushmandi K, Hashemi F, Tajik F, Hashemi M, Kumar AP, Aref AR, Zarrabi A, Khan H, Hamblin MR, Nuri Ertas Y, Samarghandian S. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. J Cell Physiol 2022;237:2309-44. [PMID: 35437787 DOI: 10.1002/jcp.30751] [Reference Citation Analysis]
62 Yang MH, Ha IJ, Lee SG, Lee J, Um JY, Ahn KS. Ginkgolide C promotes apoptosis and abrogates metastasis of colorectal carcinoma cells by targeting Wnt/β-catenin signaling pathway. IUBMB Life 2021. [PMID: 34273236 DOI: 10.1002/iub.2532] [Reference Citation Analysis]
63 Choi HS, Kim YK, Hwang KG, Yun PY. Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines. Int J Mol Sci 2020;21:E8897. [PMID: 33255409 DOI: 10.3390/ijms21238897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Crowell LL, Yakisich JS, Aufderheide B, Adams TNG. Electrical Impedance Spectroscopy for Monitoring Chemoresistance of Cancer Cells. Micromachines (Basel) 2020;11:E832. [PMID: 32878225 DOI: 10.3390/mi11090832] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
65 Chang CM, Li YF, Lin HC, Lu KH, Lin TW, Liu LC, Su KM, Chang CC. Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics. Int J Mol Sci 2021;22:4105. [PMID: 33921111 DOI: 10.3390/ijms22084105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Tong H, Li T, Gao S, Yin H, Cao H, He W. An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer. Biosci Rep 2021;41:BSR20203944. [PMID: 33289830 DOI: 10.1042/BSR20203944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
67 Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, Sharifzadeh SO, Soleymani L, Daneshi S, Hushmandi K, Khan H, Kumar AP, Aref AR, Samarghandian S. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother 2021;141:111824. [PMID: 34175815 DOI: 10.1016/j.biopha.2021.111824] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
68 Kang E, Kim S, Jeon SY, Jung JG, Kim H, Lee H, Han W. Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-β pathway. Cancer Gene Ther. [DOI: 10.1038/s41417-021-00419-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Kim NY, Jung YY, Yang MH, Um J, Sethi G, Ahn KS. Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF-κB signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells. Cellular Signalling 2022. [DOI: 10.1016/j.cellsig.2022.110433] [Reference Citation Analysis]
70 Wang Q, Wu J, Wei H, Huang H, Huang Y, Fang H, Gong X, Sun J, Wu Y, Lei C, Yu J, Hu D. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1. Int J Biochem Cell Biol 2021;138:106040. [PMID: 34246759 DOI: 10.1016/j.biocel.2021.106040] [Reference Citation Analysis]
71 Sha J, Bai Y, Ngo HX, Okui T, Kanno T. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition. Biomolecules 2021;11:893. [PMID: 34208465 DOI: 10.3390/biom11060893] [Reference Citation Analysis]
72 Kong WY, Ngai SC, Goh BH, Lee LH, Htar TT, Chuah LH. Is Curcumin the Answer to Future Chemotherapy Cocktail? Molecules 2021;26:4329. [PMID: 34299604 DOI: 10.3390/molecules26144329] [Reference Citation Analysis]
73 Mirzaei S, Paskeh MDA, Hashemi F, Zabolian A, Hashemi M, Entezari M, Tabari T, Ashrafizadeh M, Raee P, Aghamiri S, Aref AR, Leong HC, Kumar AP, Samarghandian S, Zarrabi A, Hushmandi K. Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. Life Sci 2021;:119948. [PMID: 34520771 DOI: 10.1016/j.lfs.2021.119948] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
74 Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res 2022;41:105. [PMID: 35317831 DOI: 10.1186/s13046-022-02293-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
75 Chai JY, Sugumar V, Alshanon AF, Wong WF, Fung SY, Looi CY. Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches. Cancers (Basel) 2021;13:4746. [PMID: 34638233 DOI: 10.3390/cancers13194746] [Reference Citation Analysis]
76 Thakur KK, Kumar A, Banik K, Verma E, Khatoon E, Harsha C, Sethi G, Gupta SC, Kunnumakkara AB. Long noncoding RNAs in triple-negative breast cancer: A new frontier in the regulation of tumorigenesis. J Cell Physiol 2021. [PMID: 34105151 DOI: 10.1002/jcp.30463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Abadi AJ, Zarrabi A, Gholami MH, Mirzaei S, Hashemi F, Zabolian A, Entezari M, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers. Biomolecules 2021;11:304. [PMID: 33670518 DOI: 10.3390/biom11020304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
78 Sadanandan N, Shear A, Brooks B, Saft M, Cabantan DAG, Kingsbury C, Zhang H, Anthony S, Wang ZJ, Salazar FE, Lezama Toledo AR, Rivera Monroy G, Vega Gonzales-Portillo J, Moscatello A, Lee JY, Borlongan CV. Treating Metastatic Brain Cancers With Stem Cells. Front Mol Neurosci 2021;14:749716. [PMID: 34899179 DOI: 10.3389/fnmol.2021.749716] [Reference Citation Analysis]